MedTrace Logo

A Safety, Tolerability and Efficacy Study of E7070 in Patients With Renal Cell Carcinoma

NCT00059735 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2008-03-05

No results posted yet for this study

Summary

The purpose of this study is to determine if E7070 is a safe and effective treatment for cancer of the kidneys.

Conditions

  • Kidney Neoplasms
  • Carcinoma, Renal Cell
  • Adenocarcinoma, Renal Cell

Interventions

DRUG

E7070

Sponsors & Collaborators

  • Eisai Inc.

    lead INDUSTRY

Principal Investigators

  • Murray Yule, MRCP, PhD · Eisai Limited

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-05-31
Completion
2003-12-31

Countries

  • United States
  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00059735 on ClinicalTrials.gov